TScan Therapeutics, Inc. (TCRX)
About TScan Therapeutics, Inc.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $10.3M
- Net income
- -$129.8M
- Total assets
- $228.8M
- Market cap
- $64.2M
- Operating margin
- -1315.4%
- Net margin
- -1256.8%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $10.3M
- Operating expenses
- $146.1M
- Operating income
- -$135.8M
- Income tax
- $0
- Net income
- -$129.8M
- EPS (basic)
- $-1.00
- EPS (diluted)
- $-1.00
Balance sheet
- Total assets
- $228.8M
- Current assets
- $157.2M
- Total liabilities
- $105.7M
- Current liabilities
- $18.7M
- Shareholders’ equity
- $123.1M
Cash flow
- Operating cash flow
- -$135.3M
- Investing cash flow
- $109.4M
- Financing cash flow
- -$336.0K
- Net cash flow
- -$26.3M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $64.2M
- EPS (diluted)
- $-1.0
- Shares outstanding
- 81.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 16, 2021
TScan Therapeutics, Inc. (TCRX) Stock Price
- Reported a net loss of $129.8M in FY2025.
- Revenue grew 2% from FY2021 to FY2025.
- Trading 69% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review TScan Therapeutics, Inc..
Write a review
News about TScan Therapeutics, Inc.
News & sentiment via Polygon.io
TScan Therapeutics, Inc.: frequently asked questions
Is TScan Therapeutics, Inc. an American company?
TScan Therapeutics, Inc. is a US-based company headquartered in Waltham, Massachusetts, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is TScan Therapeutics, Inc. headquartered?
TScan Therapeutics, Inc. is headquartered in Waltham, Massachusetts, United States.
Is TScan Therapeutics, Inc. publicly traded?
Yes — TScan Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol TCRX on the NASDAQ.
What does TScan Therapeutics, Inc. do?
TScan Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
